Future Healthcare 100 Online Cloud Exhibition: Launching a Journey of Innovation

Dolphin Digital Medical Industrial Park

The Dolphin Digital Healthcare Industrial Park, located in the Chengdu IC Valley of Shuangliu District, Chengdu, will provide comprehensive services for applying for Internet hospital licenses to enterprises with needs for digital healthcare and internet-based medical infrastructure construction. These services encompass full-process support, including partnerships with physical hospitals, system development, pharmaceutical warehousing and logistics, classified protection of cybersecurity, industrial synergy, and operational collaboration. This initiative aims to help more enterprises leverage the Internet hospital model to foster innovation in the digital healthcare industry. The first batch of resident enterprises comprises over 50 companies, including JD Health, Sunshine Insurance Group, Xiuzheng Pharmaceutical Group, Yangtze River Pharmaceutical Group, Jointown Pharmaceutical Group, Umai Technology, and Zhenluo Science.

Seagull Digital Medical Device Industrial Park

Leveraging Guizhou’s advantages in the big data industry and digital healthcare policies, the Seagull Digital Medical Device Industrial Park will provide comprehensive construction services to pharmaceutical companies, innovative medical institutions (such as those specializing in genetic testing, stem cell therapy, and health check-ups), and other enterprises with infrastructure needs for digital and internet-based healthcare. These services include full-process support for obtaining hospital qualifications during internet hospital development, such as facilitating partnerships with physical hospitals, system construction, and compliance with classified protection of cybersecurity standards. Additionally, the park offers end-to-end assistance for applying for “Digital Therapeutic Product Registration Certificates” to enterprises with digital therapy products. Furthermore, once enterprises obtain the necessary qualifications, the park will leverage the advantages of its internet hospital cluster to facilitate the market implementation of digital therapeutic products. It will also provide consulting services for operational system development, team building and training for online diagnosis and treatment operations, and strategic operational consulting. Seagull is committed to fostering the clustered development of digital and internet healthcare enterprises, promoting high-quality and high-level advancement of digital healthcare across China, and striving tirelessly to establish itself as a national-level demonstration industrial park in the industry.

As a pioneer in the construction and operation of China’s digital healthcare industry clusters, Taozi Health is committed to providing its partners with comprehensive, high-efficiency, and cost-effective solutions for internet healthcare infrastructure, as well as a seamless, all-encompassing service chain for internet healthcare operational support.

Emibo Innovation was founded by overseas-returnee PhDs from fields such as clinical medicine, computer simulation, and artificial intelligence. Addressing the complex challenges and substantial patient needs in hospital-based interventional procedures, the company has adopted a novel conceptual approach that integrates globally leading technologies from their respective specialties. By cross-disciplinarily merging cutting-edge advancements in clinical medicine, computer simulation, artificial intelligence, and image recognition, Emibo Innovation conducts pioneering research and development to deliver disruptive products and solutions for intelligent interventional surgery. This effort drives the digital transformation of medical technology and truly realizes precision smart healthcare. The company has completed foundational research on intelligent navigation and early warning systems for interventional embolization procedures, resulting in nine invention patent applications and two software copyright registrations. These technological achievements fill critical gaps in the field of interventional embolization and are at the global forefront. Building on this foundation, the innovation team has pioneered the development of the world’s first commercial products designed for clinical application: the AIMI Guide™ HA Intelligent Navigation and Early Warning System for Hepatic Artery Interventional Procedures, and the AIMI Guide™ Y90 Treatment Planning System for Yttrium-90 Microsphere Radioembolization. Future phases will focus on the staged development of intelligent robots for interventional surgery, specialized consumables, and smart interventional operating room solutions.

Dajian Biotech is a high-tech biomedical enterprise specializing in precision medicine, integrating the R&D, manufacturing, registration, sales, and clinical application of in vitro diagnostic (IVD) reagents. Focusing on early cancer screening and auxiliary diagnosis, Dajian Biotech leverages platforms such as PCR and NGS to develop methylation-based technologies using exfoliated tissue cells and ctDNA for the early detection and diagnosis of tumors.

The R&D pipeline includes single-cancer products for colorectal cancer, nasopharyngeal carcinoma, bladder cancer, cervical cancer, liver cancer, esophageal cancer, thyroid cancer, and endometrial cancer. It also features multi-cancer combined testing products, such as gastrointestinal tumor panels covering gastric cancer, liver cancer, colorectal cancer, and pancreatic cancer, as well as gynecological tumor panels covering cervical cancer, endometrial cancer, and ovarian cancer. Additionally, the company has an NGS-based pan-cancer product pipeline, making it the Chinese enterprise with the most comprehensive R&D pipeline in gene methylation detection.

Digital Pathology Slide Scanning SystemThe digital pathology slide scanning system can load 1–480 pathology slides at once, enabling fully automated scanning. It supports unattended operation and allows for continuous addition of slides during operation. The scanning speed is ≤40 seconds per slide (15 mm × 15 mm area at 40x magnification), with a throughput of approximately 40–60 slides per hour. The maximum scanning resolution reaches 0.17 μm/pixel. Scanning modes include single-layer, multi-layer fusion, or multi-layer stacking. The system accurately identifies tissue regions, thereby reducing scanning time and storage requirements. Multiple patented technologies ensure high-definition digital slides free from color distortion and stitching artifacts. The system can be integrated with other applications to enable functionalities such as remote consultation, pathology education, slide reading examinations, image analysis, and intelligent diagnosis.

Dejin focuses on the research and development of treatment technologies for structural heart disease, particularly those related to the mitral and tricuspid valves, providing a systematic global solution for mitral valve lesions. Product: DragonFly transfemoral venous septal edge-to-edge mitral valve repair device,Advantages: The valve clip surface is coated to accelerate endothelialization. The central occlusion mesh works in conjunction with the valve clip to enable locking at any angle, which reduces tension on the valve leaflets while effectively preventing leaflet perforation, thereby ensuring favorable long-term clinical outcomes. The device allows for independent leaflet grasping, facilitating surgical manipulation and effectively shortening procedure time. Real-time monitoring of left atrial pressure provides immediate assessment of procedural efficacy. MRI examination is safe for patients after valve clip implantation.

A one-stop platform dedicated to women’s health and beauty across the entire life cycle, leveraging advanced genomics, predictive intelligence, and digital technologies to support us and our partners in delivering comprehensive, personalized women’s health experiences.FemTec Health has completed six acquisitions globally, encompassing a beauty company, gut health and nutrition firms, a clinical trial platform, a women’s community, a reproductive health company, and a behavioral health company, thereby building a global community of three million women. The company employs 230 people worldwide and maintains offices in Athens, New York, Houston, San Diego, Barcelona, London, and Shanghai. Currently, three clinical trials are underway.

Product 1: Hera

Ovulation-Predicting Smart Bracelet for Conception and Contraception (FDA-Cleared, 500,000 Units Sold Globally)

Product 2: Venus

A Ring for Monitoring Women’s Menstrual Cycle Health, Sleep, and Mood (Leveraging Data from 4 Million Complete Menstrual Cycles to Monitor Reproductive Hormones and Ovulation Windows, Helping All Women Receive Early Disease Warnings and Track Their Physical Condition)

The development and widespread adoption of technologies such as the internet, 5G, and artificial intelligence have ushered the public into the digital age, injecting new momentum into the field of mental health. In this digital era, the health management model is gradually evolving towards an integrated online-offline approach, with collaboration between healthcare professionals and AI becoming increasingly seamless. The trend in the mental health industry will be characterized by the digitization, datafication, algorithmic integration, and intelligent enhancement of psychological services.

Haixinqing has pioneered the "Digital EAP Service Concept" within the industry. Breaking away from the limitations of traditional EAP providers, Haixinqing’s digital EAP service integrates online and offline offerings. Leveraging 5G-enabled medical technology, VR scenarios, AI-powered intelligent triage systems, and big data-driven precise matching of user needs, it enables employees to access private, customized digital EAP services.

Haoxinqing VR Diagnosis and Treatment Technology leverages virtual reality to authentically replicate offline clinical consultations within the metaverse, providing an immersive, dual-channel audiovisual sensory experience. By enhancing the fidelity of psychological treatment scenarios, it stimulates positive emotions in patients and facilitates psychotherapy within a virtual environment. Both doctors and patients can engage in voice calls, motion capture, and facial expression display within the virtual consultation room. Future updates will introduce features such as sandplay therapy, scale-based screening, psychological assessment, and psychological training, creating a comprehensive, immersive psychological experience for users.

Huimei SCRM is a SaaS-based private-domain marketing tool that leverages the WeChat ecosystem to help enterprises establish direct information outreach and academic exchanges with customers through WeChat Official Accounts. The academic platform built in this manner is what we commonly refer to as a private-domain traffic pool.
Compared with traditional marketing models, SCRM enables marketing automation by delivering targeted content to specific audiences at designated times, thereby achieving cost reduction, efficiency improvement, and centralized control over broad outreach. Furthermore, enterprise-customer connectivity is no longer constrained by time or space, facilitating high-frequency interactions with physicians. Meanwhile, data records of meetings and activities are maintained to meet compliance requirements. Finally, customer support for enterprise products can be quantified through behavioral tracking, allowing for more targeted adjustments to marketing strategies.

The advantages of Huimei SCRM are mainly reflected in the following aspects:
1. Support the creation of personalized academic portals, building private-domain platforms with unique corporate characteristics based on the brand demands and product features of enterprises;
2. Provide a representative-facing access portal to help representatives track meeting attendance progress and article sharing updates, synchronize private-domain persona tags, and offer reference recommendations;
3. Mayo Clinic provides professional academic content support and collaborates with enterprises to build a high-quality medical knowledge base;
4. VR virtual agents can effectively integrate with private-domain operations to support promotional campaigns and drive customer acquisition;
5. Combine enterprise private-domain data with Huimei’s public-domain data to obtain more comprehensive customer profile tags;

By building and operating private-domain platforms, we help enterprises:
1. Consolidate physician customer relationships and establish direct online channels to reach doctors, thereby achieving low-cost, wide-reaching academic promotion;
2. Consolidate academic resources to enable the repeated dissemination of online academic content, thereby fostering sustained brand awareness among physician customers;
3. Acquire potential customers by identifying target clients through user behavior analysis within private domain channels, helping pharmaceutical companies uncover more sales opportunities.

Beijing Cornerstone Life Technology Co., Ltd. has independently developed the “Microtumor PTC In Vitro Drug Sensitivity Testing” technology, which can perform in vitro drug sensitivity assays for over one hundred commonly used clinical oncology drugs. This technology provides robust experimental evidence to guide personalized medication for cancer patients. Addressing the industry’s critical lack of accurate techniques for predicting drug efficacy, this approach is the first to discover a novel mechanism by which primary tumor cells (including stromal components) self-assemble in vitro into 3D microstructures (microtumors). As a novel in vitro research model, microtumors accurately recapitulate the dynamics, heterogeneity, and drug sensitivity profiles of patient tumors. The technology boasts a 90% culture success rate, a two-week testing cycle, and a 93% clinical concordance rate. Related findings were published in June 2020 in the prestigious international journal Science Translational Medicine. The project has been selected for major special initiatives on disruptive technology R&D and achievement transformation in Zhongguancun, as well as the National Natural Science Foundation of China’s Original Exploration Program, and has won multiple awards in roadshows such as domestic innovation and entrepreneurship competitions.

Digital Human Health Management Solution; Integrates various smart hardware devices in the broader health sector, and through a digital human all-in-one large-screen kiosk, provides users with services such as 3D health records, posture assessment, 3D AI self-diagnosis, medical encyclopedia, and a health marketplace. Meanwhile, it connects with the BOE Health Management Service Team to deliver online and offline services from physicians and health managers, addressing users’ health management needs and pain points.

Hardware Terminal – Digital Human 3D Smart Health All-in-One Machine, which can interface with various integrated or modular smart hardware devices. It provides B-end users with standardized illustrated health kiosk solutions and offers C-end users home-based wearable modular hardware solutions. Users may purchase the complete hardware package (hardware + 3D terminal) or upgrade their existing data acquisition hardware to access 3D visualized health management services.

Functional Modules – Centered on “digital twin,” leveraging “multimodal modeling” and AI-driven algorithmic analysis to display users’ 3D health records on end-user devices, and providing services such as 3D health assessment, 3D AI self-diagnosis, posture evaluation, a medical and health encyclopedia, a “3D Time Machine,” and personalized diet and exercise recommendations; additionally, building a customer self-operated service marketplace to deliver value-added health management services for the B-side client ecosystem.

Health Management Services -- 1. Internet Hospital Specialty Centers: Provide full-cycle disease-specific management for users, including preventive screening, online consultations, offline diagnoses, follow-up visits with prescription refills, in-hospital treatments, and home-based care. 2. Membership-Based Health Management Services: Target high-net-worth individuals (and their families) with needs, willingness, and ability to pay, offering proactive, intervention-oriented health services that extend from offline to online through a membership model. Service Scope: Through dedicated healthcare teams comprising health consultants and general practitioners, and leveraging BOE Hospitals and partner hospitals, we provide integrated health management, premium medical care, and upgraded services. These offerings address all client health needs, enabling early detection, diagnosis, intervention, and treatment of diseases, thereby ensuring rapid efficacy and optimal outcomes.

Digital Anatomy Electronic Whiteboard -- Jointly developed by China's top anatomy experts and 3D engineers, this system features two standard anatomical models (male and female), including: 12 major organ systems, 12 sets of Traditional Chinese Medicine (TCM) meridians, 720 acupoints, the eight extraordinary meridians, and 3D interactive modules for common clinical diseases. It is applicable to various healthcare scenarios both within and outside hospitals, such as doctor-patient communication, medical training, patient education, and sports rehabilitation.

Internet Hospital Development Services. We provide a comprehensive, end-to-end suite of services for internet hospital development, including license application, system platform construction, integration with cybersecurity classified protection standards, and connectivity with provincial-level regulatory platforms.
Highlights:
1. Multiple Internet Hospital Bases. Zibo Economic Development Zone, Guangzhou Nansha, Chengdu Tianfu New Area, and Tianjin Binhai New Area offer medical enterprises a range of location options to meet diverse needs;
2. In-depth research on local policies, extensive implementation experience, and comprehensive client case studies;
3. Tailored solutions with one-stop, end-to-end services;

Nuoer Medical has consistently centered its core strategy on “electroencephalography (EEG),” building upon stereoelectroencephalography (SEEG) technology—an evidence-based triad integrating deep-brain EEG, MRI imaging, and clinical behavioral data. In the first phase of industrialization, the company focuses on functional neurological disorders, with product development specifically guided by clinical pain points in epilepsy diagnosis and treatment, particularly those related to SEEG surgical procedures and postoperative EEG analysis. Nuoer’s core team comprises neuroscientists, clinical experts, hardware and software industry specialists, as well as AI and big data experts. It is among the earliest innovators to focus on the SEEG field, applying MRI-compatibility to neurointerventional products and leveraging AI algorithms for automated epileptic EEG recognition.Currently, clinical trials for Nuoer’s world’s first MRI-compatible SEEG electrodes are being conducted under the leadership of Principal Investigator Hong Zhen, President of the Chinese Association Against Epilepsy. Multi-center clinical collaborations have been successfully launched with renowned epilepsy centers at seven top-tier tertiary hospitals in China, including Shanghai Huashan Hospital and Hunan Xiangya Hospital, earning endorsement from clinical experts. Furthermore, Nuoer has completed high-value patent arrangements and pre-research prototyping for its second-generation hardware platform (macro-micro SEEG electrodes integrated with AI algorithm-enabled electrodes). This advancement addresses the current challenge wherein existing SEEG electrodes fail to capture higher-frequency sample data with consistent behavioral correlation—such as high-frequency oscillations and high-frequency wavelets at 100 Hz and above—when dealing with complex pathologies in large-scale clinical settings.

In April 2022, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration officially accepted the Investigational New Drug (IND) application for NouvNeu001, Ruijian Medicine’s investigational therapy for Parkinson’s disease. Preclinical data demonstrated that, leveraging Ruijian Medicine’s proprietary high-efficiency chemical small-molecule technology for inducing functional cell regeneration, NouvNeu001 can be efficiently converted into mature dopaminergic neurons after transplantation. These neurons secrete dopamine neurotransmitters and establish neural connections with endogenous neurons, thereby exerting comprehensive therapeutic effects and alleviating Parkinsonian symptoms. Ruijian Medicine is concurrently advancing its IND application with the U.S. Food and Drug Administration (FDA), with Phase I clinical trials in humans planned for the third quarter of 2022. Meanwhile, the company’s pipeline candidate for vision impairment, NouvSight001, has achieved groundbreaking preclinical results in restoring vision. Additionally, Ruijian Medicine has attained an international breakthrough in immunotherapy by generating large quantities of high-purity, functional cytotoxic cells within two weeks.

Built on key technologies such as UCL data standardization and AI agents within complex systems, Ruiyu has developed a SaaS-based product matrix tailored for physicians, patients, and the healthcare ecosystem. This matrix addresses clinical needs in smart IoT, intelligent management, digital health records, and smart consultation, providing full-lifecycle solutions ranging from health management to comprehensive patient journey management.

Driving industrial transformation through technological innovation and perfecting the digital-intelligence closed loop via clinical applications. Through clinical management practices across multiple centers, departments, and a wide range of diseases, Ruiyu Digital Health continuously explores innovative applications of digital therapeutics, achieving a dual closed loop for disease management and data management.

One of the five strategic brands of Linjia Haoyi. With over a decade of experience in healthcare brand traffic operations and implementation, our team leverages physician agents to build branded physicians through short-video platforms, delivering sustained and actionable traffic services. Our core offerings include managed operations for medical short videos, production of medical long-form videos, training for physician agents, medical short-video production training, private-domain traffic management training, and consulting advisory services. We empower partners by sharing both immediate solutions and sustainable methodologies grounded in practical expertise.

Ruolin Cloud Clinic

Ruolin Cloud Clinic Management System is a cloud-based service platform designed for primary healthcare, aiming to enhance the operational efficiency of community medical services, enable intelligent medical operations management, and deliver a 120% improvement in customer service experience, thereby creating a patient-centered clinic with warmth. Key features include: 1) Appointment scheduling and registration; 2) Billing and execution of various medical orders; 3) Post-consultation follow-up; 4) Provision of online internet-based consultation tools.

Duobaoshi VR Visual Function Training Product
Duobaoshi VR Visual Function Training Product is a VR-based visual function training solution with a National Medical Device Registration Certificate, enabling standardized and compliant business operations.
Achieves a cross-disciplinary integration of virtual reality technology and visual function training. Patients wear VR headsets to undergo training in 360° fully virtual environments, enhancing visual function through diverse, engaging training modules and immersive experiences. The system leverages VR technology to present different information, timing, and contrast levels to each eye, creating an optimal environment for dichoptic training. This helps balance binocular perception and rapidly establish binocular visual function.

Beibeile Comprehensive Treatment Device for Myopia and Amblyopia
Beibeile Comprehensive Myopia and Amblyopia Therapy Device is a VR-type Class II medical device that integrates three major functions: red-light photobiomodulation training, accommodative training, and visual function training. It enables the eyes to undergo ciliary muscle accommodative training involving hand-eye-brain coordination, while simultaneously promoting fundus blood circulation through red-light irradiation, thereby slowing axial elongation and controlling myopia progression.
Meanwhile, Beibele leverages virtual reality (VR) technology and challenge-based games to enable users to undergo accommodative and visual function training in realistic 3D simulated environments. This approach not only improves and restores accommodative function but also mitigates the impact of visual dysfunction on myopia progression. Such immersive training significantly enhances user compliance, allowing patients to better adhere to treatment through an engaging and enjoyable experience.

Guided by the design philosophy of “Sportiness as the Foundation, Efficiency as the Priority,” the all-new BMW i3 showcases its athletic character through a sharp front fascia, fully enclosed kidney grille, newly evolved inverted-L “Angel Eyes” headlights, an intelligent drag-reduction grille, and race-inspired “shark gill” air curtains. The poised rear design fully expresses sporting aesthetics, with a newly designed rear bumper, 3D sculpted floating LED taillights, and a flatter, wider rear diffuser combining to create a robust and full-bodied visual effect. Newly styled 19-inch aerodynamic wheels paired with low-rolling-resistance tires help reduce the all-new BMW i3’s drag coefficient to 0.24 Cd, truly enabling it to glide effortlessly through the wind.
The all-new BMW i3’s powertrain and electrically excited synchronous motor deliver enhanced output and quicker response, with a maximum power of 210 kW and peak torque of 400 N·m. It accelerates from 0 to 100 km/h in just 6.2 seconds with a single motor, providing robust power across the entire speed range. This “golden combination” of the electric era vividly embodies pure driving pleasure.
Represented by the all-new BMW i3, the BMW i brand is continuously redefining market expectations for refined luxury in electric vehicles.

Yibai Technology focuses on technology empowerment for the marketing divisions of pharmaceutical and medical device companies. Leveraging Pharma MarTech, it provides comprehensive solutions across all pharmaceutical marketing scenarios, facilitating enterprises’ digital transformation in marketing.

Yibai’s independently developed 100.pMarTech SaaS platform encompasses four core product lines: 100.eMarketing for pharmaceutical digital marketing, 100.CRM+ Intelligent Representative Workbench, 100.eHospital Internet Hospital, and 100.AiData Intelligent Data Platform. It provides pharmaceutical companies with comprehensive solutions for “digital academic promotion, digital sales management, and digital doctor-patient management,” covering the entire marketing chain across “enterprise–physician–patient–pharmaceutical.” Externally, it enables the online integration of over 30 marketing scenarios; internally, it establishes an integrated marketing management system that connects multiple departments within the enterprise. This helps pharmaceutical companies create a closed-loop digital marketing ecosystem that seamlessly integrates internal and external operations, pioneering a new era of transition from digital operations to integrated management in the pharmaceutical industry.

Yibai Technology, a leading provider of digital transformation services for pharmaceutical marketing in China, has served over 1,000 pharmaceutical company clients and more than 100 association clients.

Zhejiang Cardiac Easy Smart Medical Technology Co., Ltd., established in 2005, is a national high-tech enterprise specializing in hospital-wide PACS/RIS, dynamic ultrasound acquisition, archiving and retrieval, regional imaging, medical consortium imaging, remote consultation, cloud imaging, imaging consultation, artificial intelligence for imaging, and imaging middle platforms.

The “New Basic Health” Imaging Middle Platform consists of a data middle platform and a business middle platform. Its primary objectives are to meet the rapidly growing operational demands of various hospital departments, avoid redundant system construction, improve physicians’ work efficiency, enhance data application and operational capabilities, and achieve collaborative applications across multiple departments and systems. The imaging data middle platform includes data acquisition, data governance, and data structuring, leveraging accumulated foundational medical imaging data for big data analytics, scientific research, and academic publications. The imaging business middle platform covers functional areas such as department management, process optimization, clinical applications, AI applications, research management, teaching applications, hospital accreditation, and the development of medical consortiums and medical communities. Within its business middle platform, the Wuji Cloud Imaging Platform software is the first cloud imaging product in China to receive certification for information technology application innovation (Xinchuang) and domestic production. It was the first in China to adopt distributed high-concurrency technology and is also the first regional case in China to pass the Level 5 Grade B interoperability standard. To date, it remains the largest prefecture-level city medical imaging cloud platform in China.

Zheng’an Health, established in 2019, is a digital therapeutics company grounded in evidence-based medicine and powered by industry-leading AI technology, dedicated to providing users with readily accessible digital mental health services.

Digital therapeutics (DTx) are software-driven interventions that translate widely validated medical principles into digital formats, used for the treatment, prevention, or management of diseases such as mental health disorders, diabetes, obesity, and chronic obstructive pulmonary disease (COPD). DTx can be used alone or in combination with medications or hardware devices to enhance clinical therapeutic outcomes.

Zheng’an’s digitally designed and developed digital therapeutics products have all undergone rigorous clinical validation. They effectively assist patients in the diagnosis, treatment, and management of mental and psychological disorders, providing more convenient medical services; enable physicians to deliver remote consultations, thereby liberating healthcare productivity; and help reduce costs for healthcare systems and insurance companies.

In 2021, over 300 million people in China suffered from sleep disorders, with the prevalence of insomnia among adults reaching as high as 38.2%. Sleep issues have gradually become a major concern affecting public health. To address this, Zheng’an Health has launched its first digital therapeutic product for chronic insomnia, “RuMian.” By integrating AI with Cognitive Behavioral Therapy for Insomnia (CBT-I), the product helps users improve their sleep through interactive mobile conversations. Users engage in five-minute daily conversations with a virtual sleep manager to receive personalized sleep improvement plans and complete daily tasks. Within six weeks, users can significantly reduce sleep onset latency and nighttime awakenings, break free from insomnia and medication dependence, and restore healthy sleep patterns.

Legend Capital was established in April 2001 as a fund management company under Legend Holdings, specializing in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards, established best practices in fund operations and management, accumulated comprehensive expertise in these areas, and built an ecosystem-based collaborative network across the entire investment value chain.

Legend Capital drives corporate innovation and growth through its proactive value-added service system, delivering strong investment returns across multiple sectors while advancing China’s industrial progress and social development.

Legend Capital envisions becoming an investment firm with global influence. Upholding its core value of “Prosperity with Integrity,” the firm actively fulfills its social responsibilities, signed and joined the UN-supported Principles for Responsible Investment (PRI) in 2019, and has integrated ESG-focused responsible investment into its long-term development strategy to advance sustainable development and green finance principles.

Established in Shenzhen in 2001, GTJA Investment pioneered the "themed industry investment" model within the sector. Focusing on investments in the healthcare and medical industries, the firm is led by strategic equity investments and covers all stages, including mergers and acquisitions (M&A), private equity (PE), venture capital (VC), and angel investing. Boasting one of China’s leading professional healthcare investment teams, GTJA Investment has built an ecosystem platform for healthcare industry investment and is committed to becoming a globally influential healthcare investment institution. With assets under management exceeding RMB 20 billion and 35 healthcare-focused funds, the firm has invested in over 160 companies (including more than 90 in the healthcare sector) and facilitated the successful listing of 33 companies, such as Boya Bio-pharmaceutical, Mindray Medical, Akeso, United Imaging Healthcare, Sansure Biotech, and Hotgen Biotech. Rooted in China with a global outlook, GTJA Investment has established operational centers in Shenzhen, Shanghai, Beijing, Nanjing, and Hong Kong. It is dedicated to investing in outstanding healthcare enterprises worldwide, bridging Chinese momentum with global capital and medical enterprises, and assisting entrepreneurs in building great companies.

Sequoia China is committed to helping entrepreneurs build enduring, great companies by providing its portfolio companies with abundant global resources and valuable historical expertise. As “entrepreneurs behind entrepreneurs,” Sequoia China focuses on investment opportunities in three sectors: technology, consumer, and healthcare. Over the past 17 years, Sequoia China has invested in more than 900 companies characterized by distinct technological advantages, innovative business models, and high growth potential.

After more than a decade of in-depth research and systematic investment deployment, Sequoia China has invested in over 200 healthcare companies with distinct technological characteristics and high growth potential. Its investment portfolio spans multiple subsectors, including innovative drugs, medical devices, healthcare services, precision medicine, and digital health. Among these portfolio companies, more than 45 have completed initial public offerings (IPOs) on the A-share, Hong Kong Stock Exchange, and U.S. stock markets.

Daoyuan Capital, established in 2014 and headquartered in Beijing, is a leading Chinese venture capital firm focused on the healthcare and medical industry. With regional teams in Chengdu, Shanghai, Shenzhen, and the United States, the firm is committed to leveraging capital and industrial resources to accelerate the growth of outstanding healthcare enterprises, deliver superior medical products to society, and advance human health. To date, its total investment scale has exceeded RMB 3 billion, comprising 12 RMB-denominated funds and three USD-denominated funds. The firm has invested in 75 companies, including 13 that are publicly listed and four currently undergoing IPO processes. Its core team possesses an average of over 15 years of investment experience in the healthcare and medical sector.

Matrix Partners China was founded in 2008 and manages assets exceeding RMB 50 billion. As a leading venture capital firm in the industry, it has long focused on early-stage and early-growth investments, specializing in sectors such as new technologies, hard tech, industrial digitalization, healthcare, frontier technologies, and new consumption. To date, it has invested in over 800 companies, including XPeng Motors, Li Auto, Futu Holdings, Chehaoduo Group, Ele.me, Youzan, Ronbay Technology, XGIMI, Momo, PingCAP, Peijia Medical, Career International, Kymed Diagnostics, Beisen, LexinFintech, Zi Hai Guo, Chuanzhi Education, MetaX, Jane Love, SiEngine, Megarobo, Semidynamics, X-Epic, Enzyvant Sciences, and Adimab.Over the past decade since its establishment, Matrix Partners China has built an investment team of more than 40 professionals, maintaining a strong commitment to China and a focus on early-to-mid stage ventures. Meanwhile, we firmly uphold the principle of "entrepreneurs first" and have established a robust post-investment service system. Our post-investment team, comprising over 90 professionals across ten different functions, empowers portfolio companies comprehensively in areas such as strategy, operations, and talent. We strive to deliver value to entrepreneurs in every possible way, adhering to the philosophy of providing support without causing disruption.

Changling Capital, established in 2016, is a new generation of theme-driven venture capital fund. The founding partners of Changling come from NEA (New Enterprise Associates), one of the largest venture capital funds in the United States, and were responsible for NEA’s investments in China from 2005 to 2015. In the fields of healthcare and aging, Changling Capital is committed to investing in technology-driven business model innovations, making longevity a gift of life for everyone in China’s rapidly aging society. Changling Capital has offices in Shanghai and Beijing, currently managing a total fund size of RMB 6 billion. Its investors include endowments from globally renowned universities and hospitals, foundations, pension funds, top-tier fund-of-funds, and other first-class institutional investors. With over 50 years of combined venture capital experience between our investment teams in Shanghai and Beijing, we are dedicated to continuously creating value for the growth and development of companies in emerging sectors.